摘要
目的:观察益气养阴、祛瘀生新复方(糖肾安)对糖尿病肾病(DN)炎症因子的影响。方法:将45例DN患者随机分为治疗组30例,对照组15例,两组均予西医常规治疗,治疗组在此基础上配合糖肾安治疗,疗程均为8周。观察患者临床疗效及空腹血糖(FBG)、血清总胆固醇(TC)、甘油三脂(TG)、炎症因子超敏C反应蛋白(hs-CRP)、肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)的变化。结果:治疗后总有效率治疗组为86.7%,对照组为53.3%,两组比较差异显著(P<0.05)。两组治疗后FBG,TC,TG均较治疗前明显下降(P<0.05,P<0.01);治疗组TC,TG下降优于对照组(P<0.05)。治疗后治疗组Hs-CRP,IL-6,TNF-α较治疗前显著下降(P<0.05,P<0.01),且治疗组下降明显优于对照组(P<0.05,P<0.01)。治疗后对照组Hs-CRP水平亦较治疗前明显下降(P<0.01),但IL-6,TNF-α改善不明显。结论:在西药治疗的基础上加用糖肾安,可提高DN的临床疗效,改善血脂代谢,下调相关炎症因子水平。
Objective: To observe the clinical influence of Tangshenan, a compound prescription of supplementing qi and nourishing yin and dispelling stasis to promote regeneration, on inflammation factors in diabetic nephropathy (DN). Method: . Forty-five DN patients were divided into treatment group ( n = 30) and control group (n = 15) at random. And each of the two groups was treated with western medicine routinely, and the treatment group was combined with Tangshenan on this basis of western medicine. The two groups were both for a treatment course of 8 weeks. Then the variations of patients' clinical responses, fasting blood glucose (FBG) , serum total cholesterol (TC) , Triglyceride (TG) , the inflammation factors of high-sensitivity c-reactive protein ( hs-CRP), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6), were investigated. Result: After treatment, the total effectiveness of treatment group was 86.7% , and the control group was 53.3% , with significant difference (P 〈0.05). For both the two teams, FBG, TC and TG were decreased significantly (P 〈0.05, P 〈0.01 ) after treatment. And the treatment group' s TC and TG' s decreasement was better than that in the control group. The treatment group' s Hs-CRP, IL-6 and TNF-α were decreased significantly (P 〈0.05, P 〈0.01 ) after treatment. The control group' s Hs-CRP level was also decreased significantly (P 〈 0.01 ) after treatment, but the improvement of IL-6 and TNF-α were not obvious. Conclusion: On the basis of western medicine, if combined with Tangshenan, the curative effect can be improved, the blood lipid metabolism can be improved, and the regularinflammation factors can be down-regulated.
出处
《中国实验方剂学杂志》
CAS
北大核心
2012年第16期320-323,共4页
Chinese Journal of Experimental Traditional Medical Formulae
基金
广东省中医药局课题(2060071)